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OBJECTIVES We sought to determine whether endothelial vasodilator function (EVF) in patients with type
1 diabetes was related to low-density lipoprotein (LDL) particle size (LDLPS), LDL vitamin
E content (LDLVE) or the susceptibility of LDL to oxidation (OxLDL).
BACKGROUND Impaired EVF is an early feature of diabetic vascular disease and may be related to oxidant
stress. Although small, dense LDL and oxidized LDL are features of type 2 diabetes and
predict the development of coronary artery disease, their role in type 1 diabetes is less clear.
METHODS Endothelium-dependent vasodilation was assessed in the brachial artery (flow-mediated
vasodilation [FMD]) and in the forearm resistance circulation using venous occlusion
plethysmography in response to graded doses of intrabrachial acetylcholine (ACh). Thirty-
seven patients with type 1 diabetes mellitus (DM) and 45 matched controls underwent
flow-mediated dilation, while a subset of 19 DM and 20 controls underwent plethysmography.
RESULTS Total, LDL and high-density lipoprotein cholesterol or triglycerides were not different in
DM compared with controls, but LDLPS was smaller (25.6 6 0.06 vs. 26.1 6 0.1 nm, p ,
0.05) and LDLVE was reduced (2.0 6 0.25 vs. 2.6 6 0.18 mmol/mmol LDL, p , 0.05).
Oxidative susceptibility of LDL was not different. Flow-mediated vasodilation was impaired
in DM compared with controls (3.6 6 0.6% vs. 7.1 6 0.5%, p , 0.005), as was the
vasodilator response to ACh (p , 0.05). Flow-mediated vasodilation was directly related to
LDLPS and LDLVE in both the entire study cohort and DM alone (p , 0.05), but not to
other parameters of the standard lipid profile. Similarly, endothelium-dependent vasodilation
in the resistance circulation was directly related to LDLPS and LDLVE, but not to OxLDL.
CONCLUSION These results suggest, but do not prove, that LDL particle size and LDL vitamin E may be
determinants of conduit and resistance vessel endothelial vasodilator function in type 1
diabetes. Further work will be required to prove cause and effect. (J Am Coll Cardiol 2000;
35:292–9) © 2000 by the American College of Cardiology
Impaired endothelial vasodilator function is an early feature
of both type 1 (1,2) and type 2 diabetes mellitus (3,4). The
possible promoters of endothelial dysfunction and ulti-
mately of atherosclerotic vascular disease in diabetes melli-
tus include hyperglycemia (5), hyperinsulinemia (6) and
lipid abnormalities (7). The latter has received increased
attention with the recognition of the impact of lipid-
lowering therapy on vascular disease outcomes in diabetic
subgroups in randomized clinical trials (8). Although these
studies targeted low-density lipoprotein (LDL) cholesterol,
a body of evidence suggests that triglycerides (9,10), high-
density lipoprotein (HDL) cholesterol (11) and qualitative
differences in LDL including LDL particle size (3,12)
(LDLPS), LDL vitamin E content (13) (LDLVE) and
LDL oxidative susceptibility (14) (OxLDL) may influence
endothelial function, atherogenesis and clinical outcomes.
The atherogenic potential of reduced LDLPS is thought
to be a risk factor for vascular disease independent of HDL
cholesterol and triglyceride levels (12). The LDL subclass
phenotype is influenced not only by genetic factors but also
by diet, drugs, menopausal status (15) and insulin levels and
sensitivity (16,17). Small, dense LDL is a common feature
of type 2 diabetes (18) and correlates with the extent of
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endothelial vasodilator dysfunction in this condition (3).
However, LDL particle size is not well characterized in type
1 diabetes. It is possible that the elevated peripheral insulin
levels, which are a feature of type 1 diabetes (19), might
influence LDL particle size (16,17).
Together with b-carotene, lycopene and ubiquinol 10,
vitamin E is the principal antioxidant in LDL (20) and has
been shown to correlate with the angiographic extent of
atherosclerosis (13) in nondiabetic individuals. Vitamin E
levels are decreased in type 2 diabetes (21), and the available
data in type 1 diabetes suggest platelet levels of vitamin E
are reduced (22). Whether LDLVE is reduced in young
subjects with type 1 diabetes is unclear, as is the relationship
of this antioxidant to endothelial vasodilator function.
We therefore sought to determine whether qualitative
changes in LDL including LDLVE, LDLPS and OxLDL
might contribute to endothelial vasodilator dysfunction in a
group of young patients with type 1 diabetes.
METHODS
Subjects. Thirty-seven young type 1 diabetic subjects
(DM) and 45 healthy control subjects were recruited for this
study, approved by the Human Research Ethics Committee
of Monash Medical Centre. All control subjects and dia-
betic patients provided written, informed consent. Control
subjects were excluded if there were any signs of cardiovas-
cular risk factors or disease. Diabetic subjects were all
treated with insulin. The average daily total insulin dose was
67 6 26 U (range 31 to 174 U). Duration of disease was on
average 97 6 52 months (mean 6 SD). None of the
diabetic subjects had clinical evidence of retinopathy, neu-
ropathy or nephropathy (albumin excretion rate , 20
mg/min).
General procedure. Conduit artery function was assessed
in all control and diabetic subjects using brachial artery
ultrasound. Resistance vessel arterial function was assessed
in a subgroup of 19 DM and 20 control subjects using
venous occlusion plethysmography.
Subjects attended the laboratory fasted, having refrained
from aspirin and nonsteroidal antiinflammatory drugs for at
least five days before the study and caffeine containing
beverages for at least 12 h. Each subject was given a
standardized light breakfast, before which DM received
their usual insulin dose. In DM, blood glucose levels were
documented at the time of brachial artery ultrasound and
twice during venous occlusion plethysmography studies. In
view of the possibility of significant metabolic derangement
influencing vascular measurements, a prospective decision to
exclude patients with blood glucose levels . 18 mmol/liter
was made. No patients required exclusion. All studies were
performed in the morning in a dedicated quiet climate-
controlled laboratory (22°C to 23°C) with dimmed lighting.
Brachial artery ultrasound. Endothelium-dependent and
-independent vasodilation was assessed in the brachial artery
using transcutaneous ultrasound. The method used has been
described in detail previously (23,24). In brief, ultrasound
images of the right brachial artery were obtained above the
elbow using a high-resolution machine (HDI Ultramark 9;
ATL, Seattle, Washington) with a 7- to 10-MHz linear-
array transducer. Endothelium-dependent flow-mediated
vasodilation was assessed as the percent change in arterial
diameter in response to reactive hyperemia associated with
5 min of ischemia. Endothelium-independent vasodilation
was assessed in response to a single tablet of sublingual
nitroglycerin (GTN). Recording and analysis of images
were performed, as described previously, by our group (24).
Venous occlusion plethysmography. Forearm blood flow
(ml/100 ml forearm tissue/min) measurement was achieved
by the well validated technique (25) of venous occlusion
plethysmography using a calibrated mercury in silastic strain
gauge (D.E. Hokanson, Bellevue, Washington) as described
by this group previously (26). A 20-gauge, 5-cm polyethyl-
ene catheter (Cook; Brisbane, Australia) was introduced
into the brachial artery of the nondominant forearm under
local anesthesia utilizing aseptic conditions. The arterial line
was used for on-line measurement of blood pressure and for
direct intraarterial drug infusions. The catheter was con-
nected via a minimum-dead-space saline-filled line to a
pressure transducer (Biosensors International; Singapore).
Physiological saline was infused at a rate of 0.4 ml/min
through the catheter into the brachial artery to maintain
patency. Measurement of resting blood flow was carried out
at least 30 min after insertion of the brachial artery line and
was repeated until a stable recording was obtained. Forearm
blood flow responses were measured continuously for 2 min
after infusion of each dose of drug. An average forearm
blood flow was calculated from at least five venous occlusion
cycles. Forearm vascular resistance (FVR) was calculated by
dividing mean arterial pressure by forearm blood flow and
was expressed in arbitrary units.
Drug infusion protocol. Nondominant forearm volume
was measured in each subject by water displacement to
Abbreviations and Acronyms
ACh 5 acetylcholine
ANOVA 5 analysis of variance
DM 5 study patients with type 1 diabetes mellitus
EDTA 5 ethylenediamine tetra-acetic acid
FMD 5 flow-mediated dilation
FVR 5 forearm vascular resistance
GTN 5 nitroglycerin
HBA1c 5 glycosylated hemoglobin
HDL 5 high-density lipoprotein
HPLC 5 high-performance liquid chromatography
LDL 5 low-density lipoprotein
LDLPS 5 LDL particle size
LDLVE 5 LDL vitamin E content
OxLDL 5 oxidative susceptibility of LDL
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ensure no difference in this parameter between groups. All
drugs were infused for 3 min at a rate of 0.4 ml/min before
commencing measurement of forearm blood flow. Forearm
blood flow responses were then measured continuously for
2 min while continuing infusion of each dose of drug.
Endothelium-dependent vasodilation was assessed in re-
sponse to acetylcholine chloride (ACh) (Miochol; Iolab
Pharmaceuticals; Sydney, Australia) at doses of 2.7, 9 and
27 mg/min cumulatively. Endothelium-independent vaso-
dilation was assessed in response to sodium nitroprusside
(Faulding; Melbourne, Australia) at a dose of 9 mg/min.
Biochemical techniques. ISOLATION OF LDL AND ASSESS-
MENT OF LDL PARTICLE SIZE. Using density gradient ultra-
centrifugation, LDL cholesterol was isolated from ethyl-
enediamine tetra-acetic acid (EDTA) plasma as previously
described (27). After ultracentrifugation, the LDL formed a
visible band. This was then isolated from the centrifuge tube
by aspiration, and EDTA was removed by passing the
sample through a sephadex G25 column (Pharmacia, Syd-
ney, Australia). The LDL particle diameter was assessed,
using the LDL fraction isolated by ultracentrifugation, by
nondenaturing polyacrylamide gradient gel electrophoresis
(Gradipore, Sydney, Australia) as previously described (28).
The gels were scanned to determine the distance of the
LDL peak from the origin. Particle diameter was calculated
using a regression equation derived from the position of
standards of known diameter (Cat. no: 17-0445-01; Phar-
macia Biotech, Milwaukee, Wisconsin) by plotting the log
of the standards against their positions on the scanned gel.
The coefficient of variation on a 26.1-nm quality control
sample run on every gel was 0.7%.
ASSESSMENT OF PLASMA AND LDL VITAMIN E CONTENT.
Plasma vitamin E measurement was performed using
reverse-phase high-performance liquid chromatography
(HPLC) using an ultraviolet absorption detector as de-
scribed previously (29). The vitamin E content of LDL was
measured on LDL isolated by ultracentrifugation, using
HPLC with a Spherisorb ODS-2, 5-mm analytical column
(Alltech Associates, Baulkham Hills, Australia) and with
standards purchased from Sigma Chemicals (St. Louis,
Missouri) and expressed as a ratio of LDL vitamin E to
LDL cholesterol (in mmol/mmol LDL).
ASSESSMENT OF LDL OXIDATIVE SUSCEPTIBILITY. Oxida-
tive susceptibility of LDL was assessed using the Esterbauer
technique (20) as modified by McDowell et al. (30). Copper
(5 mmol) was added to isolated LDL diluted to 150
mmol/liter cholesterol in phosphate-buffered saline. The
generation of products resulting from the oxidation of lipids
was followed by measuring absorbance at 234 nm. The lag
time was calculated as the time intercept between the line of
maximum slope of the propagation phase of this reaction
and the base-line absorbance at time 5 0.
Statistical Analysis. Clinical characteristics are expressed
as mean value 6 standard deviation. Data are expressed as
mean value 6 standard error. Student’s t-test was utilized in
the comparison of paired data (baseline characteristics,
endothelium-dependent and -independent vasodilation).
Differences between groups in the vasodilator responses to
ACh were evaluated using a two-way repeated-measures
analysis of variance (ANOVA). Simple and multiple linear
regression analyses were performed to determine the best
individual and combination of predictor variables. Statistical
significance was accepted when the p , 0.05.
RESULTS
There were no significant differences in age (24 6 5 vs.
22 6 5 years), gender distribution or body mass index
(24.7 6 0.5 vs. 23.8 6 0.5 kg/m2) between the diabetic
(DM) and control groups, respectively. Glycosylated hemo-
globin (HBA1c) levels of 8.5% indicated at least fair
glycemic control in DM, whereas duration of diabetes was
97 6 52 months.
Lipid profile. There was no difference in fasting total
cholesterol, LDL, HDL or triglyceride levels in DM com-
pared with controls (Table 1). However, LDLPS was
0.5 nm smaller and LDLVE was 23% less in DM compared
with control subjects (Table 1). There was no difference
however in OxLDL between DM and control subjects.
The LDLPS was directly related to HDL (r 5 0.26, p ,
0.05) and inversely related to TG levels (r 5 0.4, p , 0.05)
in the diabetic group, while LDLPS was correlated with
waist/hip ratio in the study cohort as a whole (r 5 0.34, p ,
0.005).
The lag time to oxidation of LDL was directly related to
LDLPS (r 5 0.36, p , 0.005) but not to LDLVE.
Insulin dose and levels. The average daily dose of insulin
in DM was 65 6 19 U (mean 6 SD). Peripheral insulin
levels were elevated in DM compared with controls (49.9 6
4.8 vs. 12.5 6 0.9 mU/ml, p , 0.005). There was no
Table 1. Baseline Lipid Measurements of the Study Groups
Characteristic
DM
(n 5 37)
Controls
(n 5 45)
Total cholesterol
(mmol/liter)
4.9 6 0.2 4.7 6 0.1
LDL cholesterol
(mmol/liter)
3.0 6 0.2 2.9 6 0.1
HDL cholesterol
(mmol/liter)
1.5 6 0.1 1.4 6 0.1
Triglycerides (mmol/liter) 0.9 6 0.1 1.1 6 0.2
Plasma vitamin E
(mmol/liter)
17.7 6 0.8 21.0 6 1*
LDL vitamin E content
(mmol/mmol LDL)
2.0 6 0.25 2.6 6 0.18*
LDL particle size (nm) 25.6 6 0.06 26.1 6 0.1*
Lag time to LDL oxidation
(min)
73.6 6 2.2 75.5 6 2.3
*p , 0.05. DM 5 subjects with diabetes mellitus. LDL 5 low-density lipoprotein.
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relationship between insulin dose or peripheral insulin levels
and LDLVE, endothelium-dependent vasodilation or pa-
rameters of the standard lipid profile. However, LDLPS
was directly related to the average daily insulin dose (r 5
0.35, p , 0.05) but not to ambient insulin levels.
Endothelium-dependent flow-mediated vasodilation.
Base-line brachial artery diameter was not different between
the diabetic or control groups (4.2 6 0.08 vs. 4.0 6
0.09 mm, p 5 NS, respectively). Flow-mediated dilation
(FMD) with reactive hyperemia was significantly reduced in
DM compared with control subjects (3.6 6 0.6% vs. 7.1 6
0.5%, p , 0.005) (Fig. 1).
There was no relationship between FMD and total
cholesterol, LDL, HDL or TG in the study cohort or DM
alone. However, FMD was a function of LDL particle size
in both the study cohort and DM alone (r 5 0.39, p ,
0.0005 and r 5 0.48, p , 0.05, respectively) (Fig. 2). FMD
was also related to LDLVE in the study cohort as a whole
(r 5 0.26, p , 0.05) and within DM alone (r 5 0.39, p ,
0.05) (Fig. 3). Despite a relationship between FMD and
LDLPS and LDLVE, there was no relationship between
FMD and the lag time to oxidation of LDL.
Within DM, FMD was inversely related to HBA1c (r 5
0.36, p , 0.05), but there was no relationship between
FMD and ambient glucose or insulin levels at the time of
measurement of FMD. Notably, FMD was directly related
to baseline arterial diameter across both groups (r 5 0.32,
p , 0.005) and correlated directly with GTN-induced
vasodilation in both the study cohort and DM alone (r 5
0.39, p , 0.0005 and r 5 0.34, p , 0.005, respectively).
GTN-induced endothelium-independent vasodilation.
The vasodilator response to sublingual GTN was impaired
in DM compared with controls (15.4 6 1.1% vs. 18.5 6
0.8%, p , 0.05) (Fig. 1). This response was directly related
to HDL in the study cohort as a whole (r 5 0.27, p , 0.05)
and inversely related to duration of diabetes (r 5 0.35, p ,
0.05). There was no relationship between GTN-induced
dilation and LDLPS, LDLVE or lag time to oxidation of
LDL.
Endothelium-dependent vasodilation in response to
ACh. Resting forearm blood flow was 50% higher in DM
compared with control subjects (3.3 6 0.3 vs. 2.0 6 0.2
ml/min/100 ml forearm, p , 0.005) and resting FVR was
lower (48.5 6 4.2 vs. 29.7 6 2.8 arbitrary units, p , 0.005).
In view of this difference in basal flow and resistance, the
absolute change in FVR (DFVR) to ACh was calculated.
The vasodilator response to ACh was impaired in DM
(ANOVA, p , 0.05), with the greatest difference between
the groups occurring at the highest dose of ACh (30
mg/min) (Fig. 4). At the maximum dose of ACh, the
absolute change in FVR was 222.3 6 3.3 vs. 239.3 6 3.7
arbitrary units, p , 0.001 in DM compared with control
subjects. The difference in vasodilator response to ACh
remained even if a subgroup of diabetic (n 5 7) and control
Figure 1. Endothelium-dependent flow-mediated dilation (A) in
diabetic (black bar) and control (white bar) subjects. FMD was
significantly reduced in DM compared with control subjects
(3.6 6 0.6% vs. 7.1 6 0.5%). Endothelium-independent GTN-
induced vasodilation (B) was also reduced in DM compared with
controls (15.4 6 1.1% vs. 18.5 6 0.8%), albeit to a lesser extent
than FMD.
Figure 2. Relationship between flow-mediated dilation in diabetic
(filled circles) and control (open circles) subjects with LDLPS.
There was a significant correlation between FMD and LDLPS in
the study cohort (A) and the diabetic group alone (B).
Figure 3. Relationship between flow-mediated dilation in diabetic
(filled circles) and control (open circles) subjects with LDLVE.
There was a significant correlation between FMD and LDLVE in
the study cohort (A) and the diabetic group alone (B).
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subjects (n 5 11) with equivalent resting blood flow were
analyzed.
There was a significant relationship between this change
in FVR and both LDLPS and LDLVE in the study cohort
as a whole (r 5 0.46, p , 0.05 and r 5 0.34, p , 0.05),
respectively, and DM alone (r 5 0.35, p , 0.05 and r 5
0.29, p , 0.05), respectively (Fig. 5).
In addition, the slope of the dose-resistance curve was
directly related to both LDLPS and LDLVE in the study
cohort (r 5 20.32, p , 0.05 and r 5 20.32, p , 0.05,
respectively; Fig. 5). However, there was no relationship
between either the slope of the dose-resistance curve or the
absolute change in FVR and the lag time to oxidation of
LDL.
Endothelium-independent vasodilation in response to
sodium nitroprusside. In view of the differences in resting
forearm blood flow between groups, the absolute change in
blood flow and vascular resistance from baseline was again
calculated. Sodium nitroprusside increased blood flow in
both groups. There was, however, no difference in the
magnitude of this response between DM and controls
(219.3 6 3.2 vs. 222.6 6 2.5 arbitrary units, p 5 NS).
Similarly, there was no difference in mean arterial pressure
between the two groups after the infusion of sodium
nitroprusside. LDLPS, LDLVE or the oxidative suscepti-
bility of LDL were not related to the vasodilator response to
sodium nitroprusside.
DISCUSSION
This study demonstrates impaired endothelium-dependent
vasodilator function of both the conduit and resistance
circulation in young subjects with type 1 diabetes, fair
glycemic control and a normal lipid profile. This vasodilator
function was related to LDLPS and LDLVE but was not
related to TC, LDL, HDL or TG. Despite demonstrating
reduced LDLPS and lower LDLVE, differences in the
oxidative susceptibility of LDL were not observed, at least
when measured using a modified Esterbauer technique (20).
Our finding of impaired endothelial function in subjects
with type 1 diabetes is consistent with a number of previous
studies in both the conduit (2,31) and resistance (1,32,33)
circulation, although some studies have shown no impair-
ment of the response to muscarinic agonists in diabetic
subjects (34–36). In this study, an impaired response to
ACh in the diabetic group persisted even when subjects
with similar resting flow to controls were analyzed, suggest-
ing that this finding was not an artefact of resting hyper-
emia. The decreased response to a nitrovasodilators in the
conduit artery but not in the resistance circulation in this
study is in agreement with most (1,2,31–34,36) but not all
previous investigations (35).
In this group of diabetics with relatively good glycemic
control, there was no difference in the routine lipid profile
compared with the control subjects. This is consistent with
previous data showing that lipid abnormalities develop in
type 1 diabetes as glycemic control deteriorates (37). We
found that endothelial function in the conduit artery was
inversely related to long-term glycemic control, but that
there was no relationship between FMD and ambient
glucose or insulin levels at the time of measurement of
FMD. Moreover, there was no relationship between FMD
and parameters of the standard lipid profile. Previous
investigators have demonstrated a relationship between
FMD and LDL in diabetic patients with suboptimal gly-
cemic control (2). This perhaps suggests that the potential
Figure 5. (A and B) The relationship between the absolute change
in forearm vascular resistance (DFVR) at peak dose of acetylcho-
line (ACh) and LDLPS (A) and LDLVE (B) in diabetic (filled
circles) and control subjects (open circles). (C and D) The
relationship between the slope of the DFVR ACh dose-response
curve and LDLPS (C) and LDLVE (D).
Figure 4. Absolute increase in forearm blood flow (A) and
absolute reduction in forearm vascular resistance (B) in diabetic
subjects (filled circles) and control subjects (open circles) during
graded intraarterial infusion of acetylcholine (ACh). The changes
in forearm blood flow and vascular resistance were attenuated in
the diabetic group compared with the control group (p , 0.05).
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for atherogenic factors to modify endothelial function in
subjects with diabetes varies with glycemic control.
The atherogenic potential of small, dense LDL is well
recognized and has been ascribed to an increased suscepti-
bility to oxidation (38), lower binding affinity for the hepatic
LDL apo B/E receptor reflected in a prolonged residence
time in plasma (39), more efficient penetration of the
arterial intima (40) and increased capacity for binding to
intimal proteoglycans (41). Thus, reduced LDL particle size
appears to represent a key modification of this lipoprotein.
Small, dense LDL is well described in type 2 diabetes (42),
but LDLPS in type 1 diabetes has not been well character-
ized. In this study, we observed LDLPS was reduced in
young patients with type 1 diabetes (glycosylated hemoglo-
bin [HBA1c] 8.5%). This contrasts with a previous obser-
vation in an older group of diabetics with poor glycemic
control (HBA1c 12.2%) (43). The LDL subclass phenotype
is influenced by genetic factors as well as external influences
including drugs, menopausal status and diet (15), and also
possibly by insulin levels and insulin sensitivity (16,17). In
keeping with this latter possibility, we observed a relation-
ship between LDLPS and the total daily insulin dose,
although there was no correlation with peripheral insulin
levels. The daily insulin dose is more likely to reflect total
insulin exposure than a single insulin level. Furthermore,
there was a correlation between LDLPS and waist/hip ratio,
a surrogate marker for insulin sensitivity (44).
We observed reduced LDLPS to be a function of both
high triglyceride levels and low HDL levels in agreement
with previous findings (45). However, it appears from older
(46) and more recent (12) data that small, dense LDL is a
risk factor for vascular disease independent of HDL and
triglyceride levels. The data on endothelial function from
this and a previous study in patients with type 2 diabetes (3)
would support this.
Epidemiological (47,48) and clinical (49) studies have
suggested a role for dietary and supplemental vitamin E,
respectively, in the prevention of coronary artery disease.
The potential mechanisms by which this chain-breaking
antioxidant exerts its effect are multiple and related not only
to its antioxidant potential. At the endothelial level, vitamin
E sequesters free radicals, responsible for the inactivation of
nitric oxide (50), while exerting beneficial influences on
leukocyte adhesion to endothelial cells (51), monocyte
transmigration (52), oxidant-mediated cytotoxicity (53) and
activated protein kinase C (54). Furthermore, LDLVE
levels may be relevant to the oxidation of LDL, which
occurs in the subintimal space (55).
Reduced antioxidant defenses, including glutathione, vi-
tamin E and vitamin C, have been observed in type 2
diabetes (21). In type 1 diabetes, platelet but not plasma
vitamin E (22) as well as vitamin C (56) are decreased. This
study is the first demonstration that LDLVE is reduced in
type 1 diabetes, as far as we are aware, and may reflect a
dietary deficit, increased consumption of this antioxidant or
abnormal metabolism (as occurs with vitamin C [57]). In
addition, elevated insulin levels, as occur in type 1 diabetes
(19), have been associated with reduced vitamin E levels
(58), although in this study we could not demonstrate a
relationship between LDLVE and ambient insulin levels or
daily insulin dose. Causation aside, we observed a relation-
ship between LDLVE and endothelial vasodilator function
in both the conduit and resistance circulation. In keeping
with this relationship, LDLVE has been shown to be
related to the severity of atherosclerosis in patients with
coronary disease (13). There was, however, no relationship
between endothelial vasodilator function and plasma vita-
min E emphasizing the importance of antioxidant localized
in LDL itself.
Although we observed reduced LDLPS and LDLVE in
DM, and a correlation between the lag phase of LDL
oxidation and LDLPS, we could not demonstrate any
difference in the oxidative susceptibility of LDL between
DM and control subjects. Moreover, there was no relation-
ship between endothelial function and oxidative susceptibil-
ity. This may be due to the sensitivity of the technique we
employed to measure oxidative susceptibility, which deter-
mines the lag phase of conjugated diene formation resulting
from copper-induced oxidation of LDL. Any change in
oxidative susceptibility produced by the alterations in
LDLPS and LDLVE may have been too small or subtle to
be detected by this method. Studies exploring the change in
lag phase of oxidation of LDL with supplemental vitamin E
have shown that approximately doubling LDLVE will
produce a significant change in this measurement (59). The
30% difference in LDLVE between DM and controls in
this study is relatively modest by comparison.
A further possibility is that LDL in this diabetic group
was already partly oxidized during isolation, as a conse-
quence of reduced antioxidant defenses (LDLVE) and
reduced particle size. This would tend to minimize any real
differences in lag time between the two groups. Measure-
ment of the oxidation status of LDL at baseline (e.g.,
thiobarbituric acid reactive substances) would provide this
information.
The fact that endothelial vasodilator function is related to
LDLVE independent of LDL oxidation is interesting. It is
possible that vitamin E in LDL is being delivered to the
endothelium, where it exerts a beneficial influence indepen-
dent of its effect on LDL by affecting activated protein
kinase C (54) and sequestering free radicals (50).
Studies that have examined endothelial function (14) and
burden of disease (60–62) in patients with clinically evident
atherosclerosis have shown a correlation between these
parameters and the oxidative susceptibility of LDL (mea-
sured using the Esterbauer technique). No study, however,
has shown a relationship between oxidative susceptibility of
LDL as measured by this technique and endothelial func-
tion in patients without overt vascular disease (63–65).
Thus, the oxidative susceptibility of LDL may correlate
better with advanced atherosclerotic disease.
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Potential limitations. While we have demonstrated an
association between LDLPS and LDLVE and endothelial
vasodilator function, we have not proved that there is a
cause-and-effect relationship. Further work manipulating
particle size and vitamin E content of LDL will be required
to take these observations further.
We cannot conclude from this study that the oxidative
susceptibility of LDL is not an important determinant of
endothelial vasodilator function. The biological relevance of
the modified Esterbauer technique to in vivo oxidation of
LDL within the arterial wall is not clear (66). Oxidative
modification of LDL may be better characterized by other
methods (67–69).
In conclusion, we have shown that reduced LDLVE and
small, dense LDL are important qualitative modifications of
LDL that contribute to impaired endothelium-dependent
vasodilation of the conduit and resistance circulation in type
1 diabetes. The in vitro oxidative susceptibility of LDL as
measured by the lag phase of conjugated diene formation is
not related to endothelial function in this group of subjects.
These data add to the growing body of evidence indicating
that qualitative modifications of LDL have an important
atherogenic effect and may indeed be independent risk
factors for vascular disease.
Reprint requests and correspondence: Dr. Ian T. Meredith,
Cardiovascular Centre, Monash Medical Centre, 246 Clayton
Road, Clayton, Melbourne, Victoria, 3168, Australia. E-mail:
ian.meredith@med.monash.edu.au.
REFERENCES
1. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-
dependent vasodilation in patients with insulin-dependent diabetes
mellitus. Circulation 1993;88:2510–6.
2. Clarkson P, Celermajer DS, Donald AE, et al. Impaired vascular
reactivity in insulin-dependent diabetes mellitus is related to disease
duration and low density lipoprotein cholesterol levels. J Am Coll
Cardiol 1996;28:573–9.
3. O’Brien SF, Watts GF, Playford DA, et al. Low-density lipoprotein
size, high-density lipoprotein concentration, and endothelial dysfunc-
tion in non-insulin-dependent diabetes. Diabet Med 1997;14:974–8.
4. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-
mediated vasodilation in patients with non-insulin-dependent diabetes
mellitus. J Am Coll Cardiol 1996;27:567–74.
5. The Diabetes Control and Complications Trial Research Group. The
effect of intensive treatment of diabetes on the development and
progression of long-term complications in insulin-dependent diabetes
mellitus. N Engl J Med 1993;329:977–86.
6. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an
independent risk factor for ischemic heart disease. N Engl J Med
1996;334:952–7.
7. Laakso M, Lehto S, Penttila I, et al. Lipids and lipoproteins predicting
coronary heart disease mortality and morbidity in patients with
non-insulin-dependent diabetes. Circulation 1993;88:1421–30.
8. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with
simvastatin improves prognosis of diabetic patients with coronary heart
disease. A subgroup analysis of the Scandinavian Simvastatin Survival
Study (4S). Diabetes Care 1997;20:614–20.
9. Lundman P, Eriksson M, Schenck-Gustafsson K, et al. Transient
triglyceridemia decreases vascular reactivity in young, healthy men
without risk factors for coronary heart disease. Circulation 1997;96:
3266–8.
10. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration
and ischemic heart disease: an eight-year follow-up in the Copenhagen
Male Study. Circulation 1998;97:1029–36.
11. Lamarche B, Despres JP, Moorjani S, et al. Triglycerides and
HDL-cholesterol as risk factors for ischemic heart disease. Results
from the Quebec cardiovascular study. Atherosclerosis 1996;119:235–
45.
12. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density
lipoprotein particles as a predictor of the risk of ischemic heart disease
in men. Prospective results from the Quebec Cardiovascular Study.
Circulation 1997;95:69–75.
13. Regnstrom J, Nilsson J, Moldeus P, et al. Inverse relation between the
concentration of low-density-lipoprotein vitamin E and severity of
coronary artery disease. Am J Clin Nutr 1996;63:377–85.
14. Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-
dependent coronary vasomotion relates to the susceptibility of LDL to
oxidation in humans. Circulation 1996;93:1647–50.
15. Austin MA. Genetic and environmental influences on LDL subclass
phenotypes. Clin Genet 1994;46:64–70.
16. Abbott WG, Lillioja S, Young AA, et al. Relationships between
plasma lipoprotein concentrations and insulin action in an obese
hyperinsulinemic population. Diabetes 1987;36:897–904.
17. Barakat HA, Carpenter JW, McLendon VD, et al. Influence of
obesity, impaired glucose tolerance, and NIDDM on LDL structure
and composition. Possible link between hyperinsulinemia and athero-
sclerosis. Diabetes 1990;39:1527–33.
18. Taskinen MR, Lahdenpera S, et alSyvanne M. New insights into lipid
metabolism in non-insulin-dependent diabetes mellitus. Ann Med
1996;28:335–40.
19. Pickup JC, Collins ACG, Walker JD, et al. Patterns of hyperinsulin-
aemia in type 1 diabetic patients with and without nephropathy.
Diabet Med 1989;6:685–91.
20. Esterbauer H, Striegl G, Puhl H, et al. Continuous monitoring of in
vitro oxidation of human low density lipoprotein. Free Radic Res
Commun 1989;6:67–75.
21. Sundaram RK, Bhaskar A, Vijayalingam S, et al. Antioxidant status
and lipid peroxidation in type II diabetes mellitus with and without
complications. Clin Sci 1996;90:255–60.
22. Karpen CW, Cataland S, O’Dorisio TM, et al. Interrelation of platelet
vitamin E and thromboxane synthesis in type I diabetes mellitus.
Diabetes 1984;33:239–43.
23. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive
detection of endothelial dysfunction in children and adults at risk of
atherosclerosis. Lancet 1992;340:1111–5.
24. New G, Timmins KL, Duffy SJ, et al. Long-term estrogen therapy
improves vascular function in male to female transsexuals. J Am Coll
Cardiol 1997;29:1437–44.
25. Hokanson DE, Sumner DS, Strandness DE Jr. An electrically
calibrated plethysmograph for direct measurement of limb blood flow.
IEEE Trans Biomed Eng 1975;22:25–9.
26. Duffy SJ, Tran BT, New G, et al. Continuous release of vasodilator
prostanoids contributes to regulation of resting forearm blood flow in
humans. Am J Physiol 1998;274:H1174–83.
27. Chung BH, Segrest JP, Ray MJ, et al. Single vertical spin density
gradient ultracentrifugation. Methods Enzymol 1986;128:181–209.
28. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma
low density lipoproteins in normal humans. J Lipid Res 1982;23:97–
104.
29. Cuesta Sanz D, Castro Santa-Cruz M. Simultaneous measurement of
retinol and alpha-tocopherol in human serum by high-performance
liquid chromatography with ultraviolet detection. J Chromatogr 1986;
380:140–4.
30. McDowell IF, McEneny J, Trimble ER. A rapid method for mea-
surement of the susceptibility to oxidation of low-density lipoprotein.
Ann Clin Biochem 1995;32:167–74.
31. Zenere BM, Arcaro G, Saggiani F, et al. Noninvasive detection of
functional alterations of the arterial wall in IDDM patients with and
without microalbuminuria. Diabetes Care 1995;18:975–82.
32. McNally PG, Watt PA, Rimmer T, et al. Impaired contraction and
endothelium-dependent relaxation in isolated resistance vessels from
patients with insulin-dependent diabetes mellitus. Clin Sci (Colch)
1994;87:31–6.
33. O’Driscoll G, Green D, Rankin J, et al. Improvement in endothelial
function by angiotensin converting enzyme inhibition in insulin-
dependent diabetes mellitus. J Clin Invest 1997;100:678–84.
298 Skyrme-Jones et al. JACC Vol. 35, No. 2, 2000
LDLPS, LDLVE and Endothelial Function February 2000:292–9
34. Elliott TG, Cockcroft JR, Groop PH, et al. Inhibition of nitric oxide
synthesis in forearm vasculature of insulin-dependent diabetic patients:
blunted vasoconstriction in patients with microalbuminuria. Clin Sci
(Colch) 1993;85:687–93.
35. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric
oxide synthesis in the human forearm arterial bed of patients with
insulin-dependent diabetes. J Clin Invest 1992;90:2548–54.
36. Smits P, Kapma JA, Jacobs MC, et al. Endothelium-dependent
vascular relaxation in patients with type I diabetes. Diabetes 1993;42:
148–53.
37. Perez A, Caixas A, Carreras G, et al. Lipoprotein compositional
abnormalities in type I diabetes: effect of improved glycaemic control.
Diabet Res Clin Pract 1997;36:83–90.
38. de Graaf J, Hak-Lemmers HL, Hectors MP, et al. Enhanced
susceptibility to in vitro oxidation of the dense low density lipoprotein
subfraction in healthy subjects. Arterioscler Thromb 1991;11:298–
306.
39. Nigon F, Lesnik P, Rouis M, et al. Discrete subspecies of human low
density lipoproteins are heterogeneous in their interaction with the
cellular LDL receptor. J Lipid Res 1991;32:1741–53.
40. Nordestergaard B, Zilversmit DB. Comparison of arterial intimal
clearance of LDL from diabetic and non-diabetic cholesterol-fed
rabbits. Differences in intimal clearance explained by size differences.
Arterioscler 1989;9:176–83.
41. La Belle M, Krauss RM. Differences in carbohydrate content of low
density lipoproteins associated with low density lipoprotein subclass
patterns. J Lipid Res 1990;31:1577–88.
42. Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes
and triglyceride metabolism in non-insulin-dependent diabetes. Arte-
rioscler Thromb 1992;12:1496–502.
43. Tsai EC, Hirsch IB, Brunzell JD, et al. Reduced plasma peroxyl
radical trapping capacity and increased susceptibility of LDL to
oxidation in poorly controlled IDDM. Diabetes 1994;43:1010–4.
44. Bjorntorp P. The relationship between obesity and diabetes. In:
Alberti KM, Zimmet P, Defronzo RA, editors. International Text-
book of Diabetes. Chichester: John Wiley & Sons, 1998;611–27.
45. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein
phenotype. A proposed genetic marker for coronary heart disease risk.
Circulation 1990;82:495–506.
46. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipopro-
tein subclass patterns and risk of myocardial infarction. JAMA
1988;260:1917–21.
47. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption
and the risk of coronary heart disease in men. N Engl J Med
1993;328:1450–6.
48. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consump-
tion and the risk of coronary disease in women. N Engl J Med
1993;328:1444–9.
49. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled
trial of vitamin E in patients with coronary disease: Cambridge Heart
Antioxidant Study (CHAOS). Lancet 1996;347:781–6.
50. Halliwell B. Free radicals, antioxidants, and human disease: curiosity,
cause or consequence? Lancet 1994;344:721–4.
51. Faruqi R, de la Motte C, DiCorleto PE. Alpha-tocopherol inhibits
agonist-induced monocytic cell adhesion to cultured human endothe-
lial cells. J Clin Invest 1994;94:592–600.
52. Navab M, Hama SY, Nguyen TB, et al. Monocyte adhesion and
transmigration in atherosclerosis. Cor Art Dis 1994;5:198–204.
53. Hennig B, Enoch C, Chow CK. Protection by vitamin E against
endothelial cell injury by linoleic acid hydroperoxides. Nutr Res
1987;1987:1253–60.
54. Ishii H, Koya D, King GL. Protein kinase C activation and its role in
the development of vascular complications in diabetes mellitus. J Mol
Med 1998;76:21–31.
55. Jessup W, Rankin SM, De Whalley CV, et al. Alpha-tocopherol
consumption during low-density-lipoprotein oxidation. Biochem J
1990;265:399–405.
56. Cunningham JJ, Ellis SL, McVeigh KL, et al. Reduced mononuclear
leukocyte ascorbic acid content in adults with insulin-dependent
diabetes mellitus consuming adequate dietary vitamin C. Metabolism
1991;40:146–9.
57. Trout DL. Vitamin C and cardiovascular risk factors. Am J Clin Nutr
1991;53 Suppl 1:322S–5S.
58. Galvan AQ, Muscelli E, Catalano C, et al. Insulin decreases circulat-
ing vitamin E levels in humans. Metabolism 1996;45:998–1003.
59. Jialal I, Fuller CJ, Huet BA. The effect of alpha-tocopherol supple-
mentation on LDL oxidation. A dose-response study. Arterioscler
Thromb Vasc Biol 1995;15:190–8.
60. Chiu HC, Jeng JR, Shieh SM. Increased oxidisability of plasma low
density lipoprotein from patients with coronary atherosclerosis in man.
Biochim Biophys Acta 1994;1225:200–8.
61. Andrews B, Burnand K, Paganga G, et al. Oxidisability of low density
lipoproteins in patients with carotid or femoral artery atherosclerosis.
Atheroscler 1995;112:77–84.
62. Regnstrom J, Nilsson J, Tornvall P, et al. Susceptibility to low-density
lipoprotein oxidation and coronary atherosclerosis in man. Lancet
1992;339:1183–6.
63. McDowell IF, Brennan GM, McEneny J, et al. The effect of probucol
and vitamin E treatment on the oxidation of low-density lipoprotein
and forearm vascular responses in humans. Eur J Clin Invest 1994;24:
759–65.
64. Gilligan DM, Sack MN, Guetta V, et al. Effect of antioxidant
vitamins on low density lipoprotein oxidation and impaired
endothelium-dependent vasodilation in patients with hypercholester-
olemia. J Am Coll Cardiol 1994;24:1611–7.
65. Chowienczyk PJ, Kneale BJ, Brett SE, et al. Lack of effect of vitamin
E on L-arginine-responsive endothelial dysfunction in patients with
mild hypercholesterolaemia and coronary artery disease. Clin Sci
1998;94:129–34.
66. Stocker R. Lipoprotein oxidation: mechanistic aspects, methodological
approaches and clinical relevance. Curr Opin Lipidol 1994;5:422–33.
67. Palinski W, Yla-Herttuala S, Rosenfeld ME, et al. Antisera and
monoclonal antibodies specific for epitopes generated during oxidative
modification of low density lipoproteins. Arterioscler 1990;10:325–35.
68. Holvoet P, Stassen JM, Van Cleemput J, et al. Oxidized low density
lipoproteins in patients with transplant-associated coronary artery
disease. Arterioscler Thromb Vasc Biol 1998;18:100–7.
69. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin
F2a–like compounds are produced in vivo in humans by a non-
cyclooxygenase, free radical catalysed mechanism. Proc Natl Acad Sci
USA 1990;87:9383–7.
299JACC Vol. 35, No. 2, 2000 Skyrme-Jones et al.
February 2000:292–9 LDLPS, LDLVE and Endothelial Function
